IL278642A - - Google Patents
Info
- Publication number
- IL278642A IL278642A IL27864220A IL27864220A IL278642A IL 278642 A IL278642 A IL 278642A IL 27864220 A IL27864220 A IL 27864220A IL 27864220 A IL27864220 A IL 27864220A IL 278642 A IL278642 A IL 278642A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670050P | 2018-05-11 | 2018-05-11 | |
| PCT/EP2019/062098 WO2019215341A1 (en) | 2018-05-11 | 2019-05-10 | Furin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278642A true IL278642A (enExample) | 2020-12-31 |
| IL278642B1 IL278642B1 (en) | 2023-06-01 |
| IL278642B2 IL278642B2 (en) | 2023-10-01 |
Family
ID=66597541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278642A IL278642B2 (en) | 2018-05-11 | 2019-05-10 | Purine inhibitors |
| IL302997A IL302997B2 (en) | 2018-05-11 | 2019-05-10 | Purine inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302997A IL302997B2 (en) | 2018-05-11 | 2019-05-10 | Purine inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11773078B2 (enExample) |
| EP (1) | EP3790871B1 (enExample) |
| JP (1) | JP7350061B2 (enExample) |
| KR (1) | KR102823187B1 (enExample) |
| CN (1) | CN112384509B (enExample) |
| AU (1) | AU2019267166C1 (enExample) |
| BR (1) | BR112020022961A2 (enExample) |
| CA (1) | CA3099863A1 (enExample) |
| IL (2) | IL278642B2 (enExample) |
| MX (1) | MX2020012034A (enExample) |
| SG (1) | SG11202010914YA (enExample) |
| WO (1) | WO2019215341A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112384509B (zh) | 2018-05-11 | 2024-04-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 弗林蛋白酶抑制剂 |
| WO2021097002A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyrimidines for treating infectious diseases |
| CA3157892A1 (en) * | 2019-11-12 | 2021-05-20 | Keith Wilcoxen | Small molecule furin inhibitors for treating infectious diseases |
| WO2021097008A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyridines for treating infectious diseases |
| CA3173921A1 (en) | 2020-04-02 | 2021-10-07 | Bp Asset V, Inc. | Furin inhibitors for treating coronavirus infections |
| FR3110345B1 (fr) | 2020-05-21 | 2024-03-29 | Agence Francaise Pour Le Dev D’Al Ula | Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques. |
| JP2024506291A (ja) * | 2021-02-03 | 2024-02-13 | ビーピー アセット ヴイ，インコーポレーテッド | 吸入用のフューリンインヒビターの製剤 |
| CN114853640A (zh) * | 2022-05-12 | 2022-08-05 | 马鞍山昂扬新材料科技有限公司 | 2-溴乙基磺酸钠的制备方法 |
| WO2024073576A1 (en) * | 2022-09-29 | 2024-04-04 | Bp Asset V, Inc. | 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof |
| DE102023126563A1 (de) * | 2023-09-28 | 2025-04-03 | Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts | Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung |
| CN119119096B (zh) * | 2024-09-09 | 2025-09-16 | 郑州药领医药科技有限公司 | 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1646160A (zh) | 2002-03-13 | 2005-07-27 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| ATE527250T1 (de) | 2002-11-21 | 2011-10-15 | Novartis Ag | 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs |
| WO2005047268A2 (en) | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
| CA2586086A1 (en) * | 2004-07-23 | 2006-01-23 | Robert E.(Deceased) Smith | Furin inhibitors |
| CA2579143A1 (en) * | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| CA2687024A1 (en) | 2007-05-09 | 2009-02-19 | Burnham Institute For Medical Research | Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens |
| AU2009216851B2 (en) * | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| CN106167483B (zh) | 2010-10-18 | 2019-02-15 | 塞伦尼斯医疗控股有限公司 | 可用于胆固醇动员的化合物、组合物和方法 |
| WO2013138666A1 (en) | 2012-03-16 | 2013-09-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| WO2013138665A1 (en) | 2012-03-16 | 2013-09-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| US9353066B2 (en) * | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
| WO2014152716A1 (en) | 2013-03-15 | 2014-09-25 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| WO2016144702A1 (en) * | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN107441094B (zh) | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
| CN112384509B (zh) | 2018-05-11 | 2024-04-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 弗林蛋白酶抑制剂 |
| CA3157892A1 (en) | 2019-11-12 | 2021-05-20 | Keith Wilcoxen | Small molecule furin inhibitors for treating infectious diseases |
-
2019
- 2019-05-10 CN CN201980046497.1A patent/CN112384509B/zh active Active
- 2019-05-10 WO PCT/EP2019/062098 patent/WO2019215341A1/en not_active Ceased
- 2019-05-10 IL IL278642A patent/IL278642B2/en unknown
- 2019-05-10 JP JP2021513005A patent/JP7350061B2/ja active Active
- 2019-05-10 IL IL302997A patent/IL302997B2/en unknown
- 2019-05-10 MX MX2020012034A patent/MX2020012034A/es unknown
- 2019-05-10 KR KR1020207035245A patent/KR102823187B1/ko active Active
- 2019-05-10 BR BR112020022961-0A patent/BR112020022961A2/pt unknown
- 2019-05-10 CA CA3099863A patent/CA3099863A1/en active Pending
- 2019-05-10 EP EP19725058.2A patent/EP3790871B1/en active Active
- 2019-05-10 SG SG11202010914YA patent/SG11202010914YA/en unknown
- 2019-05-10 AU AU2019267166A patent/AU2019267166C1/en active Active
- 2019-05-10 US US17/054,491 patent/US11773078B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021523941A (ja) | 2021-09-09 |
| IL278642B1 (en) | 2023-06-01 |
| EP3790871A1 (en) | 2021-03-17 |
| AU2019267166A1 (en) | 2020-11-26 |
| CA3099863A1 (en) | 2019-11-14 |
| MX2020012034A (es) | 2021-04-12 |
| IL278642B2 (en) | 2023-10-01 |
| KR20210021298A (ko) | 2021-02-25 |
| US20220315556A1 (en) | 2022-10-06 |
| AU2019267166C1 (en) | 2023-11-30 |
| SG11202010914YA (en) | 2020-12-30 |
| CN112384509B (zh) | 2024-04-30 |
| KR102823187B1 (ko) | 2025-06-20 |
| WO2019215341A1 (en) | 2019-11-14 |
| EP3790871C0 (en) | 2024-01-24 |
| EP3790871B1 (en) | 2024-01-24 |
| IL302997A (en) | 2023-07-01 |
| IL302997B1 (en) | 2024-04-01 |
| US11773078B2 (en) | 2023-10-03 |
| BR112020022961A2 (pt) | 2021-02-17 |
| AU2019267166B2 (en) | 2023-06-15 |
| CN112384509A (zh) | 2021-02-19 |
| JP7350061B2 (ja) | 2023-10-02 |
| IL302997B2 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021000792B8 (enExample) | ||
| AT524874A5 (enExample) | ||
| AT524834A2 (enExample) | ||
| AU2018438767B1 (enExample) | ||
| AT521543A3 (enExample) | ||
| AT524961A5 (enExample) | ||
| BR102019026286B1 (pt) | Método e aparelho para o avanço de produtos a serem moldados | |
| BR102019025884B1 (pt) | Sistema de segurança aprimorado para máquinas de operação de autopropulsão | |
| BR102019023514B1 (pt) | Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna | |
| BR112020016338B1 (pt) | Dispositivo para tratamento de tecido corporal | |
| BR112021004021B1 (pt) | Método e sistema para produzir um resíduo de rejeitos empilhável | |
| BR112021001186B1 (pt) | Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos | |
| BR112020023795B1 (pt) | Composição de recheio para um produto de chocolate à base de gordura, e seus métodos de produção | |
| BR112021000922B1 (pt) | Tela de filtro, e, método para purificar água de alimentação | |
| BR112020026077B1 (pt) | Recipiente com estrutura encaixável | |
| BR112020026721B1 (pt) | Aparelho de moldagem para modar uma folha de um material contendo alcaloides | |
| BR102019012845B1 (pt) | Montagens de guia de entrada de piso de compartimento de carga retráteis para carregamentos paletizados em aeronaves de carga e aeronave e carga | |
| BR112020023832B1 (pt) | Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral | |
| BR112020024987B1 (pt) | Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico | |
| BR112020023823B1 (pt) | Distribuidor | |
| BR112020022482B1 (pt) | Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico | |
| BR112020022658B1 (pt) | Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido | |
| BR112020022516B1 (pt) | Processo para degomagem enzimática de óleo | |
| BR112020021042B1 (pt) | Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas | |
| BR112020020812B1 (pt) | Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado |